Sign up to save your data!
Some tips to help get started:
Processing...
There are 324 active trials for advanced/metastatic breast cancer. Click on a trial to see more information.
324 trials meet filter criteria.
Sort by:
HealthScout AI summary: Eligible adult patients with advanced or metastatic solid tumors (including dedicated cohorts for TNBC and melanoma) whose disease is refractory or progressed after standard therapy may receive intratumoral STX-001, a self-replicating mRNA encoding IL-12, as monotherapy or combined with pembrolizumab. Enrollment requires an accessible lesion for injection/biopsy and ECOG 0-1.
ClinicalTrials.gov ID: NCT06249048
HealthScout AI summary: Eligible patients are adults with advanced, folate receptor alpha–expressing solid tumors—including ovarian, endometrial, cervical, non-small cell lung, triple-negative breast, pancreatic, or colorectal cancer—without uncontrolled CNS metastases or significant comorbidities. Treatment involves investigational LY4170156, a topoisomerase I inhibitor antibody-drug conjugate targeting FRα, given as monotherapy or combined with bevacizumab or carboplatin.
ClinicalTrials.gov ID: NCT06400472
HealthScout AI summary: Eligible patients are adults with advanced or metastatic solid tumors—especially those with CCNE1-amplified ovarian, endometrial, gastric/GEJ, or esophageal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, or HR+ HER2- breast cancer post-CDK4/6 inhibitor—who have exhausted standard therapies, receiving oral NKT3964, a selective CDK2 PROTAC degrader targeting the CDK2/cyclin E pathway.
ClinicalTrials.gov ID: NCT06586957
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors who have progressed after standard therapies to receive DB-1310, a HER3-targeting antibody-drug conjugate with a topoisomerase I inhibitor payload, as monotherapy or in combination with trastuzumab (HER2+ breast cancer) or osimertinib (EGFR-mutant NSCLC). Key eligibility includes measurable disease, ECOG 0-1, and no prior HER3-ADC or topoisomerase I inhibitor exposure.
ClinicalTrials.gov ID: NCT05785741
HealthScout AI summary: Eligible patients are adults with metastatic solid tumors (ECOG 0-1, measurable disease, adequate organ function) who will receive MDX2001, a tetraspecific antibody that engages T cells via CD3/CD28 and targets TROP2 and c-MET on tumor cells. The trial excludes individuals with major cardiac disease, active brain metastases, uncontrolled infections, or unresolved toxicities.
ClinicalTrials.gov ID: NCT06239194
HealthScout AI summary: Adults with unresectable, advanced, or metastatic solid tumors (including NSCLC, colorectal, HNSCC, pancreatic, ovarian, or breast cancer) that are both HLA-A*02:01 positive and harbor the TP53 R175H mutation, and who have progressed on prior therapy, may receive NT-175, an autologous T cell product genetically engineered with a TCR targeting TP53 R175H and rendered resistant to TGF-β mediated immunosuppression. Treatment includes leukapheresis, lymphodepletion (fludarabine/cyclophosphamide), NT-175 infusion, and short-course subcutaneous IL-2.
ClinicalTrials.gov ID: NCT05877599
HealthScout AI summary: Adults with advanced solid tumors—such as high grade serous ovarian, squamous NSCLC, triple negative breast, gastric, colorectal, esophageal, bladder, head and neck, and select gynecologic cancers—who have progressed on standard therapies receive oral VLS-1488, a selective inhibitor of the mitotic kinesin KIF18A, given in 28-day cycles. Patients with active CNS metastases, prior KIF18A inhibitor exposure, or MSI-H/dMMR tumors are excluded.
ClinicalTrials.gov ID: NCT05902988
HealthScout AI summary: This study enrolls adults with advanced, unresectable, or metastatic solid tumors—including MSS colorectal, head and neck, melanoma, and non-small cell lung cancers—who have progressed on or are intolerant to standard therapies, to receive SNS-101, a novel monoclonal antibody targeting VISTA for selective immunomodulation in the tumor microenvironment, as monotherapy or in combination with the anti-PD-1 antibody cemiplimab.
ClinicalTrials.gov ID: NCT05864144
HealthScout AI summary: This trial enrolls adults with selected advanced solid tumors—including NSCLC, renal cell carcinoma, melanoma, platinum-resistant ovarian cancer, nasopharyngeal carcinoma, and triple negative breast cancer—who have progressed after specific prior therapies, to evaluate the safety and dosing of KFA115 (a novel immunomodulatory small molecule, presumed to enhance anti-tumor immunity) as monotherapy and in combination with pembrolizumab. Exclusion criteria include significant cardiac, autoimmune, and interstitial lung diseases, as well as history of severe hypersensitivity to study drugs.
ClinicalTrials.gov ID: NCT05544929
HealthScout AI summary: Adults with advanced unresectable or metastatic melanoma (non-uveal/mucosal), head and neck squamous cell carcinoma, non-small cell lung cancer, triple negative breast cancer, or classical Hodgkin lymphoma who have progressed on prior PD-1/PD-L1 therapy are eligible to receive CTX-8371, an investigational bispecific antibody targeting PD-1 and PD-L1 designed to overcome checkpoint inhibitor resistance, as monotherapy.
ClinicalTrials.gov ID: NCT06150664
